Arvinas, a biotech company specializing in targeted protein degradation drugs, will present its first quarter 2026 financial results and provide a corporate update on May 12, 2026, via a live webcast. The company is known for developing the first FDA-approved PROTAC drug, VEPPANU, for advanced breast cancer, and is advancing several investigational drugs for neurodegenerative diseases and cancers. Investors and interested parties can access the webcast on Arvinas' website, with a replay available after the event. This update is important as it offers insights into the company's progress and financial health amid ongoing drug development.
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
Charles Hoskinson, co-founder of Cardano, warned that Bitcoin might lose its top cryptocurrency status if its governance structure fails to effectively address quantum computing challenges. He emphasized that Bitcoin's rigidity in making major upgrad...
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
Singapore's Monetary Authority has slightly increased the rate of appreciation of the Singapore dollar's policy band for the second time, aiming to preempt inflation risks from rising oil prices. Despite core inflation remaining low at 1.6% in June, ...
POSCO International, South Korea's largest trading company, is piloting the tokenization of real commercial invoices on the Injective blockchain in partnership with LG CNS. This pilot creates a unified, transferable onchain record for trade receivabl...
